The β-adrenergic blocking potencies and the antiarrhythmic activities of metabolites of befunolol hydrochloride (BFE-60) were compared with BFE-60 and propranolol. In anesthetized rats and dogs, anti-isoproterenol activities of M I and M II were less potent than BFE-60 but were almost equal to activities of propranolol, while the activity of M III was about 0.1 times as potent as propranolol. M V, M VII, M IX, M I-PG, M I-2G and M II-4G were less effective. In the isolated rat uterus, M II showed an anti-isoproterenol activity that was 0.5 times greater than BFE-60 and propranolol, and the activity of M I was 0.15 times as potent as BFE-60, while those of M III, M V, M VII, M IX, M I-PG, M I-2G and M II-4G were 100 times less potent than BFE-60. Regarding local anesthetic activity using guinea pig cornea, M I showed a similar potency to BFE-60 but M II was 0.2 times as potent as BFE-60. On the
l-adrenaline-induced ventricular arrhythmia in anesthetized dogs, M I was as potent as BFE-60, but M II being less potent than BFE-60 was similar to the potency of propranolol. M I also completely prevented the ouabain-induced ventricular arrhythmia in anesthetized dogs in the same manner as BFE-60 and propranolol, while M II was less potent. These results indicate that in β-adrenergic blocking activity, M I and M II have much the same potency as propranolol, and in antiarrhythmic activity, M II is less effective than M I which had a similar potency to propranolol. M III, M V and M VII also had β-adrenergic blocking activities but to a much lesser extent. The other metabolites showed little activity.
View full abstract